For the first time, the U.S. Food and Drug Administration (FDA) has approved the use of a ketamine-like drug as a stand-alone therapy for adults with treatment-resistant depression (TRD).

The FDA did not express concern about the stability of the ketamine submission batches, which achieved 18 months of stability without issue, and no new preclinical and clinical studies were requested.

Avesta's approach involves working with patients' mental health providers to tailor treatments to individual needs.

Around that time, a doctor friend told him about ketamine for treatment-resistant depression. It wasn’t an FDA- approved treatment. But Winograd says it saved his life. But for every success s ...

His death was attributed to "acute effects of ketamine" with accidental drowning as the manner of death.

Medicare doesn’t currently cover ketamine infusions for mental health conditions, as the Food and Drug Administration (FDA) only approves ketamine as a general anesthetic. However, it may cover ...

The charges against Marcus Jordan, the son of NBA star Michael Jordan, have changed since his initial arrest on Feb. 4 in ...

Ketamine, a dissociative anesthetic, has carved itself a spot in the world of mental health care over the past two decades.

Avesta Ketamine and Wellness (Avesta), the leading provider of monitored ketamine care in the Washington, D.C., Maryland and ...

After the rejection of Lykos Therapeutics’ MDMA-based PTSD treatment tempered excitement for psychedelic therapeutics, a ...

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...